The functional characteristics of optogenetic gene therapy for vision restoration.


Journal

Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 26 09 2019
accepted: 09 07 2020
revised: 20 06 2020
pubmed: 31 7 2020
medline: 4 3 2021
entrez: 31 7 2020
Statut: ppublish

Résumé

Optogenetic strategies to restore vision in patients blind from end-stage retinal degenerations aim to render remaining retinal neurons light-sensitive. We present an innovative combination of multi-electrode array recordings together with a complex pattern-generating light source as a toolset to determine the extent to which neural retinal responses to complex light stimuli can be restored following viral delivery of red-shifted channelrhodopsin in the retinally degenerated mouse. Our data indicate that retinal output level spatiotemporal response characteristics achieved by optogenetic gene therapy closely parallel those observed for normal mice but equally reveal important limitations, some of which could be mitigated using bipolar-cell targeted gene-delivery approaches. As clinical trials are commencing, these data provide important new information on the capacity and limitations of channelrhodopsin-based gene therapies. The toolset we established enables comparing optogenetic constructs and stem-cell-based techniques, thereby providing an efficient and sensitive starting point to identify future approaches for vision restoration.

Identifiants

pubmed: 32728765
doi: 10.1007/s00018-020-03597-6
pii: 10.1007/s00018-020-03597-6
pmc: PMC7904736
doi:

Substances chimiques

Channelrhodopsins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1597-1613

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : LI2846/1-1
Organisme : St. Cross College, University of Oxford
ID : 1616156
Organisme : Uniklinikum Giessen und Marburg (DE)
ID : UKGM 15/2020 MR
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M009998/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205151/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S026266/1
Pays : United Kingdom

Références

Nat Neurosci. 2013 Oct;16(10):1499-508
pubmed: 23995068
N Engl J Med. 2015 May 14;372(20):1887-97
pubmed: 25938638
Science. 2010 Jul 23;329(5990):413-7
pubmed: 20576849
Front Neuroanat. 2017 Oct 24;11:92
pubmed: 29114208
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Bull World Health Organ. 2004 Nov;82(11):844-51
pubmed: 15640920
Front Neural Circuits. 2013 Jan 31;7:8
pubmed: 23386813
Lancet. 2017 Aug 26;390(10097):849-860
pubmed: 28712537
Curr Biol. 2018 Sep 10;28(17):2739-2751.e3
pubmed: 30122532
Curr Biol. 2015 Aug 17;25(16):2111-22
pubmed: 26234216
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3515-20
pubmed: 16186328
Nat Commun. 2019 Mar 15;10(1):1221
pubmed: 30874546
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11211-11216
pubmed: 28973921
Sci Rep. 2018 Sep 19;8(1):14076
pubmed: 30232391
Nat Neurosci. 2008 Jun;11(6):667-75
pubmed: 18432197
Hum Mol Genet. 2018 Aug 1;27(15):2589-2603
pubmed: 29718372
Exp Eye Res. 1997 Jul;65(1):45-50
pubmed: 9237863
J Neurosci. 2010 Jun 30;30(26):8745-58
pubmed: 20592196
Mol Ther. 2011 Feb;19(2):293-301
pubmed: 21045809
Vision Res. 2014 Aug;101:41-50
pubmed: 24863584
Hum Gene Ther Methods. 2012 Feb;23(1):18-28
pubmed: 22428977
PLoS One. 2009 Nov 05;4(11):e7679
pubmed: 19893752
Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3211-21
pubmed: 27309625
Front Neurosci. 2018 Nov 02;12:789
pubmed: 30450028
Mol Ther. 2019 Jun 5;27(6):1195-1205
pubmed: 31010741
PLoS Biol. 2015 May 07;13(5):e1002143
pubmed: 25950461
Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):16009-14
pubmed: 18836071
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5574-83
pubmed: 25489083
Front Cell Neurosci. 2015 Aug 25;9:330
pubmed: 26379501
Science. 2003 Jan 10;299(5604):245-7
pubmed: 12522249
Sci Rep. 2017 Apr 13;7:45487
pubmed: 28406473
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1288-1294
pubmed: 29625451
Mol Vis. 2013 Jun 12;19:1310-20
pubmed: 23805038
Hum Gene Ther. 2016 Feb;27(2):134-47
pubmed: 26751519
EMBO Mol Med. 2016 Nov 2;8(11):1248-1264
pubmed: 27679671
Pflugers Arch. 2012 Apr;463(4):537-48
pubmed: 22160437
Ophthalmol Retina. 2019 Mar;3(3):201-210
pubmed: 31014695
Invest Ophthalmol Vis Sci. 1978 Jun;17(6):489-98
pubmed: 659071
Mol Ther. 2015 Oct;23(10):1562-71
pubmed: 26137852
Mol Ther. 2011 Jul;19(7):1220-9
pubmed: 21505421
Trends Neurosci. 2014 Jan;37(1):1-9
pubmed: 24287308
EMBO Mol Med. 2014 Aug 04;6(9):1175-90
pubmed: 25092770
Lancet. 2014 Mar 29;383(9923):1129-37
pubmed: 24439297
Nature. 2016 Jan 21;529(7586):345-50
pubmed: 26735013
Eur J Neurosci. 2012 Jan;35(1):34-43
pubmed: 22211741
Mol Ther. 2015 Jan;23(1):7-16
pubmed: 25095892
Development. 2002 Jul;129(14):3513-22
pubmed: 12091320
Neuron. 2006 Apr 6;50(1):23-33
pubmed: 16600853

Auteurs

Moritz Lindner (M)

The Nuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. moritz.lindner@ndcn.ox.ac.uk.
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. moritz.lindner@ndcn.ox.ac.uk.
Institute of Physiology and Pathophysiology, Department of Neurophysiology, Philipps University, Marburg, Germany. moritz.lindner@ndcn.ox.ac.uk.

Michael J Gilhooley (MJ)

The Nuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Department of Neuroophthalmology, Institute of Ophthalmology, London, UK.

Stuart N Peirson (SN)

The Nuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Steven Hughes (S)

The Nuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Mark W Hankins (MW)

The Nuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. mark.hankins@eye.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH